Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377(20):1919-29. Abstract

Aupérin A et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28(13):2181-90. Abstract

Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract

Chansky K et al. The IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2017;12(7):1109-21. Abstract

Chen HHW et al. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget 2017;8(37):62742-58. Abstract

Cheng AL et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). Proc ASCO 2017;Abstract 4001.

Detterbeck FC et al. The eighth edition lung cancer stage classification. Chest 2017;151(1):193-203. Abstract

Durm GA et al. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Proc ASCO 2018;Abstract 8500.

Faivre-Finn C et al. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Proc ESMO 2018;Abstract 1363O.

Siegel RL et al. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7-34. Abstract

Wani SQ et al. Radiation therapy and its effects beyond the primary target: An abscopal effect. Cureus 2019;11(2):e4100. Abstract